CHGCY:OTO-Chugai Pharmaceuticals Co. Ltd. ADR (Unsponsored) (USD)

COMMON STOCK | Drug Manufacturers - General | OTC Pink

Last Closing

USD 18.09

Change

0.00 (0.00)%

Market Cap

USD 18.41B

Volume

0.13M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Chugai Pharmaceutical Co Ltd is engaged in the manufacture, sale, import and export of pharmaceuticals products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-02 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 244.17B
RHHBF Roche Holding AG

N/A

USD 231.29B
RHHVF Roche Holding AG Participation

N/A

USD 224.97B
RHHBY Roche Holding Ltd ADR

N/A

USD 224.18B
NVSEF Novartis AG

N/A

USD 219.86B
SNYNF Sanofi

N/A

USD 120.49B
GLAXF GSK plc

N/A

USD 79.44B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 67.69B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 66.04B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 50.41B

ETFs Containing CHGCY

1638:TSE 6.85 % 0.00 %

N/A

N/A
JPMV:PA 2.60 % 0.00 %

N/A

N/A
OSXJ:XETRA 2.60 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.03% 55% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.03% 47% F 45% F
Trailing 12 Months  
Capital Gain 27.66% 94% A 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.66% 94% A 78% C+
Trailing 5 Years  
Capital Gain 58.92% 88% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.92% 88% B+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 7.18% 79% B- 51% F
Dividend Return 7.18% 67% D+ 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.24% 21% F 59% D-
Risk Adjusted Return 17.85% 61% D- 52% F
Market Capitalization 18.41B 75% C 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.